YANG XU^1,#, HONGYUN LI^1,#, GE YOU^2,*

BIOCELL, Vol.48, No.2, pp. 229-237, 2024, DOI:10.32604/biocell.2023.045030 - 23 February 2024

Abstract Background: Colorectal cancer (CRC) constitutes the leading cause of death worldwide. Chemoresistance and tumor immune evasion are critical contributors to therapeutic failure in cancer patients. CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) is aberrantly expressed in various cancers and can regulate tumor immunity. However, its role in chemoresistance and tumor immunity of CRC is not well understood. Methods: Online bioinformatics tools were used to analyze expression and prognosis of CMTM6 in CRC patients. CRC cells were transfected with si-CMTM6. Subsequently, the effects on CRC cell viability and chemoresistance were investigated by CCK-8 assay and flow cytometer.… More > Graphic Abstract

JIANFA WU^1,2,#, QIANYI LIAO^3,#, LI ZHANG^1,2,#, SUQIN WU^1,2,*, ZHOU LIU^1,2,*

Oncology Research, Vol.32, No.2, pp. 373-391, 2024, DOI:10.32604/or.2023.031404 - 28 December 2023

Abstract The impact of different iron metabolism processes (DIMP) on ovarian cancer remains unclear. In this study, we employed various gene chips and databases to investigate the role of DIMP in the initiation and development of ovarian cancer. cBioPortal was used to determine mutations in DIMP-associated genes in ovarian cancer. Kaplan-Meier plotter was used to examine the influence of DIMP on the prognosis of ovarian cancer. By analyzing 1669 serous ovarian cancer cases, we identified a range of mutations in iron metabolism genes, notably in those coding for the transferrin receptor (19%), melanotransferrin (19%), and ceruloplasmin… More >

WEI HU^1,#, THOMAS WARTMANN^2,#, MARCO STRECKER², ARISTOTELIS PERRAKIS², ROLAND CRONER², ARPAD SZALLASI³, WENJIE SHI^2,*, ULF D. KAHLERT^2,*

Oncology Research, Vol.32, No.1, pp. 227-239, 2024, DOI:10.32604/or.2023.043053 - 15 November 2023

Abstract Transient receptor potential (TRP) channels are strongly associated with colon cancer development and progression. This study leveraged a multivariate Cox regression model on publicly available datasets to construct a TRP channels-associated gene signature, with further validation of signature in real world samples from our hospital treated patient samples. Kaplan-Meier (K-M) survival analysis and receiver operating characteristic (ROC) curves were employed to evaluate this gene signature’s predictive accuracy and robustness in both training and testing cohorts, respectively. Additionally, the study utilized the CIBERSORT algorithm and single-sample gene set enrichment analysis to explore the signature’s immune infiltration… More > Graphic Abstract

SANDRA STICKLER¹, BARBARA RATH¹, MAXIMILIAN HOCHMAIR², CLEMENS LANG³, LUKAS WEIGL⁴, GERHARD HAMILTON^1,*

Oncology Research, Vol.31, No.1, pp. 13-22, 2023, DOI:10.32604/or.2022.027281 - 01 March 2023

Abstract Small cell lung cancer (SCLC) is frequently disseminated and has a dismal prognosis with survival times of approximately two years. This cancer responds well to initial chemotherapy but recurs within a short time as a globally chemoresistant tumor. Circulating tumor cells (CTCs) are held responsible for metastasis, the extremely high numbers of these cells in advanced SCLC allowed us to establish several permanent CTC cell lines. These CTCs are distinguished by the spontaneous formation of large spheroids, termed tumorospheres, in regular tissue culture. These contain quiescent and hypoxic cells in their interior and are associated… More >

AJIT C. DHADVE^1,2, PRITHA RAY^1,2

BIOCELL, Vol.46, No.1, pp. 75-86, 2022, DOI:10.32604/biocell.2022.016346 - 28 September 2021

Abstract Progression, relapse, and therapy resistance are the most challenging features of cancer therapy that have been postulated to be driven by Cancer Stem Cell (CSC) population. This enigmatic subpopulation of cancer cells has therefore emerged as promising therapeutic candidate. We earlier reported enrichment of CSC-like side population (SP) with increasing resistance towards Cisplatin and Paclitaxel either alone or in combination in epithelial ovarian cancer (EOC) cells. This SP population is a small proportion of the total population of cancer cells characterised with high expression of drug transporters, a unique feature of stem cells and thereby… More >

ZAHRA NASRPOUR NAVAEI¹, GHAZALEH KHALILI-TANHA¹, AMIR SADRA ZANGOUEI², MOHAMMAD REZA ABBASZADEGAN³, MEYSAM MOGHBELI^1,3,*

Oncology Research, Vol.29, No.4, pp. 235-250, 2021, DOI:10.32604/or.2022.025323 - 31 August 2022

Abstract Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the first-line drugs, is of great importance in the chemotherapy of various tumors. However, a significant percentage of cancer patients are resistant to CDDP treatment. Due to the CDDP side effects on normal tissues, the diagnosis of CDDP resistance is required to suggest the most efficient therapeutic strategies for cancer patients. Several molecular mechanisms and signaling pathways are associated with CDDP response. The PI3K/AKT signaling pathway has a pivotal role in the transmission of extracellular signals into the cells… More >

Elda A. Flores-Contreras¹, Everardo González-González^2,3, Ana I. Zarazúa-Niño¹, Elsa N. Garza-Treviño¹, Natalia Martínez-Acuña¹, Viviana C. Zomosa-Signoret⁴, Román Vidaltamayo⁴, Gerardo E. Muñoz-Maldonado⁵, Raquel Garza-Guajardo⁶, Manuel de J. García-Solís⁷, Alejandro Abarca-Blanco³, Ana M. G. Rivas-Estilla¹, Carlos Córdova-Fletes^1,*

Oncologie, Vol.23, No.3, pp. 373-392, 2021, DOI:10.32604/oncologie.2021.017786 - 26 September 2021

Abstract Breast cancer (BC) is one of the leading causes of death in women worldwide. A major challenge in BC is chemoresistance, which is often modulated by epigenetic regulators such as long non-coding RNAs (lncRNAs). Because these regulator lncRNAs may play diverse roles, determining their specific pathways and/or functions is crucial to identify possible biomarkers and/or therapeutic targets for BC. In this study, we used gene expression microarrays in order to identify lncRNAs related to the BC biology. We found, among six differentially expressed (DE) lncRNAs, that the expression of lnc-ERP44-3:6 was consistently down-regulated in all breast… More >

Xuehua Luo^1,#, Huijun Xie^2,#, Li Han¹, Qiaoming Zhong³, Meng Xu^4,*, Ling Jin^1,*

Oncologie, Vol.23, No.3, pp. 425-438, 2021, DOI:10.32604/Oncologie.2021.017267 - 26 September 2021

Abstract Tetrandrine has a variety of anti-tumor effects including against or reversal of tumor chemoresistance, but its mechanism of against tumor chemoresistance is still unclear. Therefore, the analytical method of network pharmacology and molecular docking was used to investigate the mechanism by which tetrandrine acts in tumor chemoresistance. We used public databases (PubChem, SwissADEM, SwissTargetPrediction) to obtain the physicochemical information and targets of tetrandrine, and used gene databases (GeneCards and OMIM) to collected disease targets, respectively. The intersection targets of disease and drug were analyzed by RStudio. We built protein-protein interaction network through the STRING database,… More >

Jianing Yi^*, Shuai Chen^*, Pingyong Yi^†, Jinlin Luo^*, Meng Fang^*, Yang Du^*, Lianhong Zou^*, Peizhi Fan^*

Oncology Research, Vol.28, No.5, pp. 519-831, 2020, DOI:10.3727/096504020X15960154585410

Abstract 5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for breast cancer. However, acquired chemoresistance leads to a loss of its efficacy; methods to reverse are urgently needed. Some studies have shown that pyrotinib, an ErbB receptor tyrosine kinase inhibitor, is effective against HER2+ breast cancer. However, whether pyrotinib sensitizes 5-FU-resistant breast cancer cells to 5-FU is unknown. We hypothesized that the combination of pyrotinib and 5-FU would show synergistic antitumor activity, and pyrotinib could reverse 5-FU resistance in HER2+ breast cancer cells in vitro and in vivo. Our data showed that pyrotinib inhibited the growth… More >

Weili Min^*1, Liangzhang Sun^†1, Burong Li^‡, Xiao Gao^*, Shuqun Zhang^*, Yang Zhao^*

Oncology Research, Vol.28, No.9, pp. 857-872, 2020, DOI:10.3727/096504021X16203818567367

Abstract EMT confers increased metastatic potential and the resistance to chemotherapies to cancer cells. However, the precise mechanisms of EMT-related chemotherapy resistance remain unclear. c-Src-mediated caspase 8 phosphorylation essential for EMT in lung adenocarcinoma cell lines preferentially occurs in cells with the mesenchymal phenotype, resulting in chemoresistance to cisplatin plus paclitaxel in patients with resectable lung adenocarcinoma and a significantly worse 5-year PFS. Cisplatin killed lung adenocarcinoma cells regardless of caspase 8. Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of caspase 8, during which FADD interacted with RIPK1 to activate More >